Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective
{{output}}
Background: Capivasertib has gained US Food and Drug Administration approval in combination with a hormonal-based regimen (eg, fulvestrant) for managing hormone receptor-positive (HR+) and human epidermal growth factor receptor 2... ...
